<DOC>
	<DOCNO>NCT01319370</DOCNO>
	<brief_summary>The current study aim show efficacy twice daily application 5 % Minoxidil Topical Foam ( MTF ) formulation compare placebo temple region male patient androgenetic alopecia 24 week well gain long-term data efficacy safety 5 % MTF male subject AGA temple vertex region , period 2 year . Objective subjective efficacy measure compare baseline . Moreover , patient get equal treatment measurement vertex region enable comparison efficacy 5 % Minoxidil Topical Foam temple baseline also vertex region . Additionally safety assessment perform throughout whole study .</brief_summary>
	<brief_title>Effectiveness Safety Minoxidil Foam Versus Placebo Foam Androgenetic Alopecia</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Minoxidil</mesh_term>
	<criteria>Male , age 18 70 year old , general good health Exhibits male AGA base discernable hair loss temple vertex region rating HamiltonNorwood Scale III vertex VI ( See Appendix 1 ) Subjects give consent study thorough explanation personally sign date informed consent document indicate subject , informed pertinent aspect trial Willing maintain hairstyle , hair length hair color throughout study Subjects willing able comply schedule visit , treatment plan , minitattoo trial procedure Accepting Information form plus accept signing Informed Consent form Known hypersensitive minoxidil , hair dye ( pphenylenediamine ) , tattoo ink , fragrance , hair gel vehicle component Current 4 week date back use medical shampoo solution include Ketoconazole like ( e. g. Terzolin® ) target region interfere CTM examination method Current 3 month date back use topical treatment target region take 2 consecutive week interfere CTM ( topical corticosteroid , aminexil , minoxidil , estrogens ) Current 3 month date back use systemic treatment ( drug dietary supplement ) take 2 consecutive week interfere CTM examination method ( beta blocker , cimetidine , diazoxide , isotretionin , corticosteroid , vitamin A intake 10000 IU per day ) Current 12 month date back use Finasteride ( Propecia® , FinaHair® , etc . ) , Dutasteride similar product Within past 12 month undergo chemotherapy receive cytotoxic agent well radiation and/or laser/surgical therapy scalp Current prior enrollment investigational medication ( drug ) study within 4 week prior study initiation Presence hair transplant , hair weave nonbreathable wig hair bond Current 2 month date back severe diet present history eat disorder Any dermatological disorder scalp target region possibility interfere CTM examination method , fungal bacterial infection , seborrheic dermatitis , psoriasis , eczema , folliculitis , scar scalp atrophy Untreated persist hypertension Active hair loss history within past 3 month include diffuse telogen effluvium , alopecia areata , scar alopecia Other severe , acute chronic medical condition may lead hair loss interfere interpretation trial result ( e. g. untreated hypothyroidism ) Individuals institutionalize court regulatory order</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>